MX2014000522A - Composicion y metodo para tratar virus del papiloma humano (vph). - Google Patents

Composicion y metodo para tratar virus del papiloma humano (vph).

Info

Publication number
MX2014000522A
MX2014000522A MX2014000522A MX2014000522A MX2014000522A MX 2014000522 A MX2014000522 A MX 2014000522A MX 2014000522 A MX2014000522 A MX 2014000522A MX 2014000522 A MX2014000522 A MX 2014000522A MX 2014000522 A MX2014000522 A MX 2014000522A
Authority
MX
Mexico
Prior art keywords
compositions
hpv
relates
composition
present
Prior art date
Application number
MX2014000522A
Other languages
English (en)
Inventor
Brigitte Evrard
Marie Piette
Isabelle Coïa
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45877205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014000522(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Publication of MX2014000522A publication Critical patent/MX2014000522A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones liofilizadas que comprenden cidofovir, hidroxipropilmetilcelulosa (HPMC) o hidroexietilcelulosa (HEC) y opcionalmente un plastificante. En particular, la presente invención se refiere a tales composiciones que forman una matriz sólida porosa en forma de hoja. La invención también se refiere a métodos para producir tales composiciones. La invención se refiere además a tales composiciones para utilizar en el tratamiento de infecciones por virus del papiloma humano (HPV) y malignidades asociadas con HPV, en particular lesiones por HPV y cáncer cervical.
MX2014000522A 2011-07-15 2012-07-13 Composicion y metodo para tratar virus del papiloma humano (vph). MX2014000522A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508473P 2011-07-15 2011-07-15
EP11174193 2011-07-15
PCT/EP2012/063796 WO2013010942A1 (en) 2011-07-15 2012-07-13 Composition and method for treating hpv

Publications (1)

Publication Number Publication Date
MX2014000522A true MX2014000522A (es) 2014-05-30

Family

ID=45877205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000522A MX2014000522A (es) 2011-07-15 2012-07-13 Composicion y metodo para tratar virus del papiloma humano (vph).

Country Status (12)

Country Link
US (1) US9211338B2 (es)
EP (1) EP2731588B1 (es)
JP (1) JP2014520834A (es)
KR (1) KR20140054067A (es)
CN (1) CN103889400A (es)
AU (1) AU2012285969A1 (es)
BR (1) BR112014000877A2 (es)
CA (1) CA2841851A1 (es)
CL (1) CL2014000110A1 (es)
EA (1) EA201490220A1 (es)
MX (1) MX2014000522A (es)
WO (1) WO2013010942A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201490220A1 (ru) 2011-07-15 2014-07-30 Фемалон С.П.Р.Л. Композиция и способ лечения hpv
US20200253994A1 (en) * 2019-02-11 2020-08-13 Chemistryrx Pyrimidine derivative containing compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
CN1698643A (zh) * 2005-05-27 2005-11-23 山东恒瑞医药科技发展有限公司 西多福韦脂质体及其制备方法
AU2006292507A1 (en) * 2005-09-15 2007-03-29 Umd, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
EP1837020A1 (en) * 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
EA201490220A1 (ru) 2011-07-15 2014-07-30 Фемалон С.П.Р.Л. Композиция и способ лечения hpv

Also Published As

Publication number Publication date
US9211338B2 (en) 2015-12-15
BR112014000877A2 (pt) 2017-02-21
CA2841851A1 (en) 2013-01-24
CN103889400A (zh) 2014-06-25
EP2731588A1 (en) 2014-05-21
EP2731588B1 (en) 2016-04-06
CL2014000110A1 (es) 2014-10-24
US20140170219A1 (en) 2014-06-19
JP2014520834A (ja) 2014-08-25
EA201490220A1 (ru) 2014-07-30
NZ620042A (en) 2015-09-25
WO2013010942A1 (en) 2013-01-24
KR20140054067A (ko) 2014-05-08
AU2012285969A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
EP3584251A3 (en) Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
MX2018002301A (es) Composiciones de glucano y usos de las mismas.
HK1242997A1 (zh) 作為廣譜人類乳頭狀瘤病毒(hpv)疫苗的乳頭狀瘤病毒樣顆粒(vlp)
MX2012002942A (es) Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX340830B (es) Vacuna neumococica y usos de la misma.
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
TN2011000656A1 (en) Pharmaceutical composition for emergency contraception
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
EP1984388A4 (en) HPV ANTIGENES, VACCINE COMPOSITIONS AND RELATED METHODS
MY161601A (en) Films and compositions comprising the same
MX2013014033A (es) Composicion descongelante.
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
BRPI0810959A2 (pt) "proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícular semelhante ao vírus (vlp) hp11, método para produzir uma proteína l1 do hpv,vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína método para prevenção de condiloma acuminado ou infecções por hpv e método para prevenção de condiloma acuminado ou infecções por hpv.
WO2017192418A8 (en) Therapeutic hpv vaccine combinations
BRPI0810951B8 (pt) proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
WO2010025370A3 (en) Preparation of ranolazine
MX2014000522A (es) Composicion y metodo para tratar virus del papiloma humano (vph).
EP3254693A4 (en) Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent
EP4226936A3 (en) Non-neuroinvasive viruses and uses thereof
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
GEP201706769B (en) Composition of tiacumicin compounds